In summary, our data confirm that PIM1 induces resistance to ALK inhibitors in NB cell lines and also demonstrate the potential for combined pharmacological inhibition of ALK and PIM1 in patients with ALK-positive, high-risk NB. The gene discussed is ALK; the disease is neuroblastoma.